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Purpose
To investigate whether the sequence of HD IL-2 and a
checkpoint inhibitor, Ipilimumab, will have additive or
synergistic efficacy or toxicity when used in rapid
sequence.
Schema
Adult patients with Stage IV or unresectable Stage III
metastatic melanoma who are eligible to receive HD
IL-2, treatment naïve or have received prior adjuvant
therapy are randomized to a sequential administration
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Figure 1 Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and
Ipilimumab Yervoy®) in patients with metastatic melanoma (proclivity 02).
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of 4 doses of Ipilimumab or 4 cycles of HD IL-2 dosed
according to their package inserts (figure 1). Fifty of the
patients will start with one drug and 50 the other. The
second drug will begin as soon as practically possible,
without waiting for relapse. Entry criteria have recently
been amended to include prior treatment with anti-
PD-1 or anti-PDL-1. Twelve US sites are currently
enrolling patients. An independent Data and Safety
Monitoring Committee oversees the study. The primary
endpoint is the proportional one year survival in the
ITT population and a protocol defined population of
patients who have received at least half of the planned
doses of both study drugs. Clinical response and pro-
gression free survival will also be assessed. The primary
endpoint is the proportional one year survival in
the ITT population and a protocol defined population
of patients who have received at least half of the
planned doses of both study drugs. Clinical response
and progression free survival will also be assessed.
Current status
Twelve US sites are currently enrolling patients. To date
16 patients have been enrolled, 9 on the Ipilimumab
first and 7 on the HD IL-2 first arms. No synergistic
toxicity has been observed, but one death occurred in
the HD IL-2 arm and one colectomy on the Ipilimumab
arm, both prior to administration of the other drug.
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